Recombinant Pig Tumor necrosis factor receptor superfamily member 6 (FAS)

What is Tumor Necrosis Factor Receptor Superfamily Member 6 (FAS) and what are its alternative names?

FAS (also known as APT1, FAS1, or TNFRSF6) is a cell surface receptor that belongs to the tumor necrosis factor receptor superfamily. It forms the death-inducing signaling complex (DISC) upon ligand binding, which can trigger apoptosis. FAS plays a critical role in the immune system regulation and has been associated with cancer mechanisms . While human FAS consists of 335 amino acids with a molecular weight of approximately 37.7 kDa, pig FAS maintains similar structural domains with species-specific variations in sequence.

How does the structure of pig FAS compare to human and rat FAS?

Pig FAS maintains the core structural elements found in other mammalian FAS proteins, including the extracellular domain containing cysteine-rich regions for ligand binding, a transmembrane domain, and an intracellular death domain for signal transduction. Sequence homology analysis indicates considerable conservation between species, particularly in functional domains involved in ligand binding and death domain signaling. The extracellular domain typically contains similar cysteine-rich motifs essential for proper protein folding and FasL interaction .

What is the primary function of FAS in cellular processes?

The primary function of FAS is to regulate programmed cell death (apoptosis) when activated by its ligand (FasL). Upon binding with FasL, FAS forms the death-inducing signaling complex (DISC), which initiates a cascade of caspase activation, ultimately leading to cell death. This mechanism is critical for immune system regulation, elimination of potentially autoreactive lymphocytes, and maintenance of cellular homeostasis . Research has demonstrated that Fas-derived signals have a particularly rapid effect, killing most cells within hours of stimulation, whereas TNFRp55 and TNFRp75-associated signals result in cell death within 2-3 days after engagement by ligand .

What expression systems are most effective for producing recombinant pig FAS?

Based on research with similar proteins, mammalian expression systems like HEK-293 cells are typically most effective for producing functional recombinant FAS proteins, as they provide appropriate post-translational modifications and protein folding . For pig FAS expression, researchers should consider the following methodological approach:

• Clone the CDS region of pig FAS from subcutaneous fat cDNA or synthesize the sequence based on genomic databases

• Insert the sequence into a mammalian expression vector with an appropriate promoter (e.g., CMV)

• Incorporate an affinity tag (His-tag or Fc-tag) for purification

• Transfect HEK-293 cells using lipid-based transfection or electroporation

• Select stable cell lines using appropriate antibiotics

• Verify expression via Western blotting

This approach has proven successful for rat FAS expression and can be adapted for pig FAS with species-specific optimizations .

What purification strategies yield the highest purity and activity for recombinant pig FAS?

To obtain high-purity, active recombinant pig FAS, a multi-step purification strategy is recommended:

Current protocols typically achieve >90% purity as determined by SDS-PAGE, with endotoxin levels below 1.0 EU per μg of protein . For optimal biological activity, the protein should be formulated in sterile PBS at pH 7.4 and stored as lyophilized powder or in small aliquots at -80°C to maintain functionality .

How can researchers verify the biological activity of purified recombinant pig FAS?

Functional verification of recombinant pig FAS can be performed through several complementary assays:

• Ligand binding assay: Measure binding affinity to recombinant FasL using surface plasmon resonance or ELISA-based methods

• Apoptosis inhibition assay: Assess the protein's ability to inhibit FasL-induced apoptosis in Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically in the range of 2-10 μg/mL in the presence of 20 ng/mL recombinant human Fas ligand

• Cell surface expression: If using a cell-based system, confirm membrane localization using immunofluorescence with anti-FAS antibodies

• Western blot analysis: Verify correct molecular weight and immunoreactivity

These validation methods ensure that the recombinant protein maintains proper folding and biological activity necessary for downstream applications .

How does recombinant pig FAS protein function in apoptosis regulation compared to other species?

When comparing apoptotic efficiency, it's crucial to consider several factors:

• The aggregation state of the receptor (membrane-bound versus soluble)

• Expression levels on the cell surface

• Cell type-specific variations in downstream signaling molecules

Research has demonstrated that optimal cell killing by FAS is dependent on a critical, low to intermediate cell surface expression level. High levels of FAS expression can paradoxically inhibit cell death, suggesting a regulatory mechanism that may be conserved across species . When designing experiments to compare pig FAS function with other species, researchers should ensure standardized expression levels and use physiologically relevant stimuli like membrane-bound FasL rather than antibodies, which can produce inconsistent results .

What role does pig FAS play in adipocyte biology and collagen regulation?

Recent research has revealed unexpected roles for FAS beyond apoptosis regulation, particularly in adipocyte biology. Studies in Zongdihua pig primary adipocytes have demonstrated that FAS regulates expression of collagen and its crosslinking via lysyl oxidase .

Experimental evidence shows that overexpression of FAS in pig adipocytes leads to:

• Significantly higher levels of COL3A1 (P<0.05)

• Lower levels of lysyl oxidase (LOX) (P<0.01)

These findings suggest that FAS participates in extracellular matrix remodeling in adipose tissue, potentially influencing fat deposition and tissue architecture. The mechanism appears to involve post-translational modifications, as analysis of pig FAS identified multiple phosphorylation sites that may regulate its non-apoptotic functions . This represents an important area for future research, particularly in understanding species-specific metabolic processes and potential implications for agricultural applications.

How can researchers effectively study FAS-mediated signaling pathways using recombinant pig FAS?

To study FAS signaling pathways effectively, researchers should consider these methodological approaches:

• Generation of chimeric receptors: Create fusion proteins composed of the extracellular domain of CD40 and the intracellular and transmembrane domains of pig FAS to study specific downstream signaling events in isolation

• Controlled receptor aggregation: Use systems that allow for inducible receptor clustering to mimic physiological activation, as membrane-bound FasL or aggregated soluble FasL consistently triggers apoptosis, whereas antibodies may act as either death agonists or antagonists

• Live cell imaging: Employ fluorescently tagged signaling components to visualize DISC formation and subsequent signaling events in real-time

• Proteomic analysis: Use immunoprecipitation followed by mass spectrometry to identify novel interaction partners specific to pig FAS

• Genetic manipulation: Utilize CRISPR/Cas9 to generate specific mutations in pig cell lines to evaluate the contribution of particular domains or residues to signaling outcomes

For robust experimental design, it's important to include appropriate controls such as FADD/MORT1-deficient cells, as FADD/MORT1 and caspase-8 are required for FAS-mediated apoptosis .

What are the key considerations when designing experiments to study pig FAS-FasL interactions?

When designing experiments to study pig FAS-FasL interactions, researchers should consider:

• Form of FasL stimulus: Membrane-bound FasL provides more consistent apoptotic triggering than soluble forms or antibodies. Studies have shown that only extensive FAS aggregation by membrane-bound FasL or aggregated soluble FasL consistently triggers apoptosis, whereas antibodies can act as death agonists or antagonists

• Expression level optimization: Maintain physiologically relevant FAS expression levels, as optimal cell killing depends on a critical, low to intermediate cell surface expression level. High expression levels can paradoxically inhibit apoptosis

• Species compatibility: Ensure compatibility between pig FAS and the FasL source. While cross-species activation often occurs, binding affinity can vary

• Temporal considerations: Monitor responses over appropriate timeframes, as FAS-mediated apoptosis typically occurs within hours of stimulation

• Cell type selection: Different cell types exhibit varying sensitivities to FAS-mediated apoptosis based on their intracellular signaling components

A comprehensive experimental design should include appropriate controls to account for these variables and enable robust interpretation of results.

How should researchers interpret contradictory results when studying FAS-mediated apoptosis?

Contradictory results in FAS research often stem from methodological variations. To interpret such discrepancies:

• Evaluate stimulation methods: Results obtained using anti-FAS antibodies versus natural ligand can differ significantly. Studies with anti-FAS antibodies have produced conflicting results on FAS signaling, particularly regarding the role of the Bcl-2 family in this process. Use physiological ligand (FasL) for most relevant outcomes

• Consider receptor density: FAS activation is highly dependent on receptor clustering efficiency, which varies with surface expression levels. Document and standardize FAS expression levels

• Examine cell-type specific factors: Different cell lineages express varying levels of inhibitory proteins like c-FLIP that can modulate FAS sensitivity

• Assess experimental timing: The kinetics of FAS-mediated apoptosis can vary based on stimulus strength and downstream signaling efficiency

• Review experimental readouts: Different assays (caspase activity, phosphatidylserine externalization, membrane permeability) measure distinct aspects of the apoptotic process and may yield varying results depending on the timepoint examined

For example, studies have revealed that Bcl-2 or Bcl-xL did not block FasL-induced apoptosis in lymphocytes or hepatocytes, demonstrating that signaling for cell death induced by FAS and the pathways to apoptosis regulated by the Bcl-2 family are distinct. This contradicts some earlier findings using antibody-based activation .

What cross-species considerations should be accounted for when using recombinant pig FAS in experimental systems?

When working with recombinant pig FAS across species, researchers should account for:

• Receptor-ligand compatibility: While FAS-FasL interactions often work across species, binding affinity may vary. Validate interaction using binding assays before conducting functional studies

• Downstream signaling variations: Species-specific differences in death domain structure may affect recruitment efficiency of signaling adaptors like FADD

• Cell type susceptibility: Different cell lineages across species may express varying levels of regulatory proteins that modulate FAS sensitivity

• Counter-regulatory mechanisms: Species-specific differences in inhibitory proteins like c-FLIP or decoy receptors may influence experimental outcomes

• Protein stability considerations: Optimize buffer conditions for pig FAS stability, which may differ from human or mouse proteins

To account for these variables, include appropriate controls such as species-matched FAS-FasL pairs and comparative studies with human or mouse systems when interpreting results from cross-species experiments.

What are common challenges in expressing and purifying functional recombinant pig FAS?

Researchers frequently encounter these challenges when working with recombinant pig FAS:

To maximize success, researchers should consider expressing only the extracellular domain (ECD) of pig FAS with appropriate tags for detection and purification, as demonstrated successfully with rat FAS where the extracellular domain (Met 1-Lys 170) was fused with a polyhistidine tag at the C-terminus .

How can researchers overcome inconsistent apoptotic responses when using recombinant pig FAS in research?

Inconsistent apoptotic responses when using recombinant pig FAS often stem from several factors:

• Receptor aggregation variability: Ensure consistent receptor clustering by using membrane-bound FasL or properly aggregated soluble FasL rather than antibodies, which can produce inconsistent results

• Cell line heterogeneity: Establish clonal cell populations with verified FAS expression levels rather than using heterogeneous populations

• Signaling threshold variations: Optimize FAS expression to intermediate levels, as both very low and very high expression can lead to reduced apoptotic responses

• Pre-existing cell death resistance: Verify the status of downstream apoptotic pathway components (FADD, caspase-8) in your experimental system

• Reagent quality inconsistency: Use freshly prepared or properly stored reagents, as FasL activity can diminish over time with repeated freeze-thaw cycles

Methodologically, researchers can improve consistency by establishing standardized protocols for:

• FasL preparation and quantification

• Verification of receptor expression levels before each experiment

• Using multiple complementary apoptosis assays (Annexin V/PI staining, caspase activity, DNA fragmentation)

• Including appropriate positive controls (known FAS-sensitive cells) in each experimental set

What quality control measures are essential for validating recombinant pig FAS before experimental use?

To ensure reliable experimental outcomes, implement these quality control measures:

• Purity assessment: Verify >90% purity using SDS-PAGE and/or size exclusion chromatography

• Endotoxin testing: Confirm endotoxin levels <1.0 EU per μg of protein using the LAL method to prevent non-specific immune activation

• Structural integrity verification: Perform circular dichroism or thermal shift assays to confirm proper protein folding

• Functional validation: Measure biological activity through:

  • Binding affinity to FasL using surface plasmon resonance

  • Ability to inhibit FasL-induced apoptosis in appropriate cell lines (e.g., Jurkat cells)

  • For membrane-incorporated FAS, verify cell surface localization via immunofluorescence

• Stability assessment: Conduct accelerated stability studies at different temperatures to establish optimal storage conditions and shelf-life

• Batch consistency: Implement comparability studies between production batches to ensure consistent performance

Establishing these quality control parameters before experimental use will significantly improve reproducibility and reliability of research findings involving recombinant pig FAS.

What novel applications are emerging for recombinant pig FAS in agricultural and biomedical research?

Emerging applications for recombinant pig FAS span both agricultural and biomedical domains:

• Meat quality improvement: Understanding FAS roles in adipocyte biology and collagen regulation opens avenues for modulating meat tenderness and fat marbling characteristics in pigs

• Xenotransplantation advancement: As pigs are considered potential organ donors for humans, understanding species-specific differences in FAS-mediated immune regulation could help develop strategies to prevent rejection

• Comparative immunology: Pig FAS provides a valuable model for studying evolutionary conservation of death receptor signaling across species

• Agricultural disease resistance: Elucidating roles of FAS in pig immune responses could inform breeding strategies for disease-resistant animals

• Drug development platforms: Recombinant pig FAS could serve as a screening tool for compounds that modulate apoptosis in a species-specific manner

These emerging applications highlight the expanding utility of recombinant pig FAS beyond basic apoptosis research into translational agricultural and biomedical applications.

How might research on pig FAS inform our understanding of human disease mechanisms?

Comparative studies between pig and human FAS can provide unique insights into disease mechanisms:

• Metabolic disorders: The role of pig FAS in regulating collagen and its crosslinking via lysyl oxidase suggests potential involvement in fibrosis and tissue remodeling relevant to human metabolic diseases

• Cancer biology: Understanding species-specific variations in FAS-mediated apoptosis sensitivity could reveal novel regulatory mechanisms relevant to cancer therapy resistance

• Immunological disorders: Pigs share significant immunological similarities with humans, making pig FAS studies valuable for understanding dysregulated immune responses in human diseases

• Tissue engineering applications: Knowledge of how pig FAS influences extracellular matrix components could inform biomaterial development for tissue engineering

The pig represents an excellent translational model for human diseases due to similarities in size, physiology, and genome, making insights from pig FAS research particularly relevant to human health applications.

What technological advances might improve our ability to study FAS signaling mechanisms in pig models?

Emerging technologies poised to advance pig FAS research include:

• CRISPR/Cas9 genome editing: Generation of precise FAS mutations or reporter systems in primary pig cells or pig models to study signaling dynamics in physiologically relevant contexts

• Single-cell analysis platforms: Characterization of cell-to-cell variability in FAS expression and signaling responses within heterogeneous tissues

• Organoid technology: Development of pig-derived 3D tissue models that better recapitulate in vivo FAS signaling compared to traditional cell culture

• Spatial transcriptomics and proteomics: Mapping FAS expression and signaling network components with spatial resolution in pig tissues

• Computational modeling: Integration of pig-specific protein structures and signaling parameters to predict FAS pathway behaviors under various conditions

• Advanced imaging techniques: Implementation of high-resolution imaging to visualize FAS clustering and signaling complex formation in real-time